HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost.

Abstract
The objective of this study was to assess the effect on serum lipid levels of the substitution of simvastatin for fluvastatin at a dose ratio of 8:1 (fluvastatin to simvastatin). A secondary objective was to determine the number of patients at goal lipid levels before and after this substitution. The study included 60 outpatients with hyperlipidemia who had received a constant dose of fluvastatin for at least 6 weeks. After a baseline 12-hour lipid profile (total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein [LDL]) was obtained, patients were switched from fluvastatin to simvastatin at an 8:1 dose ratio. Patients were instructed to split the simvastatin tablets in half with a pill splitter and to take one half-tablet at bedtime. A repeat lipid profile and liver function testing were performed after 6 to 8 weeks of simvastatin therapy. Lipid components were compared before and during simvastatin therapy using a paired t test. Target LDL levels were based on guidelines issued by the National Cholesterol Education Program. Fifty-six patients completed the study. No change in lipid components was observed, except for a statistically significant decrease in LDL. The majority of patients had a decrease in LDL levels, rather than an increase, after the conversion to simvastatin. Six patients required a dose increase of simvastatin in response to increased LDL levels. Forty-one percent of patients achieved goal LDL levels with simvastatin, compared with 30% with fluvastatin. Four patients withdrew from the study, two because of troublesome side effects and two for failure to complete the protocol. The results show that simvastatin can be substituted for fluvastatin at a dose ratio of 8:1 without loss of lipid control in the majority of patients and that by using this ratio and splitting tablets, significant cost savings can be realized.
AuthorsJ P Rindone, G Arriola
JournalClinical therapeutics (Clin Ther) 1998 Mar-Apr Vol. 20 Issue 2 Pg. 340-6 ISSN: 0149-2918 [Print] United States
PMID9589824 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Fatty Acids, Monounsaturated
  • Indoles
  • Lipids
  • Fluvastatin
  • Simvastatin
Topics
  • Aged
  • Anticholesteremic Agents (blood, economics, therapeutic use)
  • Cholesterol, LDL (blood)
  • Costs and Cost Analysis
  • Fatty Acids, Monounsaturated (blood, economics, therapeutic use)
  • Female
  • Fluvastatin
  • Humans
  • Hypercholesterolemia (blood, drug therapy, economics)
  • Indoles (blood, economics, therapeutic use)
  • Lipids (blood)
  • Male
  • Risk Factors
  • Simvastatin (blood, economics, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: